A new alternative rabies bait vaccine strain named ERAG3G, which is applicable to wild animals, was developed to eliminate rabies in South Korea. In this study, the safety and immunogenicity of the strain was evaluated in Korean raccoon dogs. The ERAG3G was propagated in BHK/T7-9 cells. Korean raccoon dogs were administered ERAG3G (1 ml, 10
INTRODUCTION
Rabies causes about 55,000 human deaths per year, indicating that it is a dangerous public health problem and one of the most important zoonoses in the world (1) remain the main wildlife vector in Korea (2) . The estimated Korean raccoon dog and stray dog population is 260,000, and the wild animal bite incidence, including bites from raccoon dogs, has been 4.5% among 2,310 bites reported since 2011. Raccoon dog rabies has affected high-risk rabies regions in two Korean provinces, and the epizootic disease has recently extended into southern areas of the Han River (3) . Although the eradication of sylvatic rabies by a trapvaccination-release program is optimum, wild animals, in-250 cluding the raccoon dog, are difficult to trap (4) . In addition, most raccoon dogs are too aggressive to administer a parenteral vaccination; intramuscular vaccination is not usually possible, as they are stray, free-ranging, and fierce dogs.
Oral rabies vaccination (ORV) with a modified live virus via the oral route has been successful in field trials to prevent rabies in wild animals and has contributed to the development of a commercial bait vaccine for the SAG2 strain in France (5, 6) . Several types of vector vaccines, including a canarypox-rabies glycoprotein recombinant vaccine, a recombinant adenovirus-vectored vaccine, and a vaccinia-recombinant glycoprotein (V-RG) virus for wild animals such as raccoon dogs and foxes, have been commercialized. The distribution of ORV has contributed to a rapid decrease in animal rabies in many countries (7~10).
As ORV has helped prevent the spread of wild animal rabies in European countries and the USA, the Korean Veterinary Authority has distributed a bait vaccine (V-RG) to highrisk rabies regions. The result of ORV has been a drastic reduction in rabies cases in Korea (11) . Nevertheless, human vaccinia infection cases have been reported: two women with a chronic skin disease were exposed to V-RG (12) The ERAG3G strain has been considered as oral rabies vaccine candidate for wild raccoon dogs. In this study, the safety and immunogenicity of the ERAG3G strain were evaluated in wild raccoon dogs.
MATERIALS AND METHODS

Cells and viruses
Murine neuroblastoma (NG108-15) cells were maintained in DMEM supplemented with 5% fetal bovine serum at 37℃ in a 5% CO 2 incubator. NG108-15 cells were used to propagate the recombinant ERAG3G strain, which was constructed in 2011 using a reverse genetic system (2). The ERAG3G strain was deposited in the Korean Veterinary Culture Collection (Accession number: KVCC-VR1500046).
After propagation, the ERAG3G strain was titrated in 96-well microplates using 10-fold dilutions. The microplates were incubated for 3 days, after discarding supernatant, and 
Safety and immunogenicity of the ERAG3G strain in raccoon dogs
This experimental design was submitted to the laboratory animal ethics committee (QIA, Seoul, Korea) and was approved (QIA2013-668). The wounded raccoon dogs were bred for treatment before releasing to where they were caught. Six-month-old raccoon dogs, which were RABV sero-negative, were divided into three groups. Groups 1 and 2 included four raccoon dogs each that were inoculated with the ERAG3G strain (1 ml, 10 8.0 fluorescent assay infectious dose, FAID 50 / ml) via the oral route using a syringe without a needle and via the intramuscular route, respectively. Two raccoon dogs in the control group remained untreated except for taking blood. The control group was bred with Group 1.
After administering the vaccine, all raccoon dogs were kept in a designated place to watch their behavior. All raccoon dogs were monitored daily for adverse effects, including anorexia, prostration, anxiety, agitation, aggression, and paralysis. Blood was collected from all raccoon dogs, including the control group, 5 and 10 weeks after inoculation.
Serological assay
The VNA titer was determined by a fluorescent antibody virus neutralization (FAVN) test (14) . to IU/ ml was made by using the mean value of the OIE standard serum (14) .
RESULTS
Safety and immunogenicity of the ERAG3G strain in raccoon dogs
All raccoon dogs were sero-negative for RABV VNA IU/ ml 70 days after inoculation (Fig. 1) . Two raccoon dogs in Group 3 remained RABV sero-negative throughout the test, confirming that no contact transmission had occurred between the vaccinated and control animals.
DISCUSSION
Raccoon dogs play a key role in transmitting the disease in Northeast Asia, including Korea, and the ferret badger is the major vector species in Taiwan (14~16). Each country has made efforts to control RABV through the mass vaccination of pets and domestic animals. Government policy has led to a significant decrease in human and animal rabies cases in many countries (17) . Nevertheless, the ability to completely eliminate rabies is limited because 80% dog vaccination coverage is required for complete eradication (18) . Therefore, a new more effective approach is desired to overcome this limitation. infected neurons than highly pathogenic street strains (23) .
Therefore, we assume that the ERAG3G strain may increase the expression of G protein in the infected cells. We also demonstrated that 4-and 6-week-old mice administered the ERA strain at a titer of 10 7.5 FAID 50 / ml via the intramuscular or intracranial route were pathogenic 6 days after inoculation, whereas mice inoculated with 10 8.5 FAID 50 / ml of the ERAG3G strain did not display any clinical signs after a 15-day observation period (24) . Another study reported that the ERAG333 strain containing Glu at position 333 was not pathogenic to mice that were > 7 days old (25) . Furthermore, orally immunizing mice with the ERAG3G strain induced complete protection (24) .
In our study, the safety and immunogenicity of the 
